Structure Stock Rises on Positive Data From Oral GLP-1 Study

Dow Jones

Mar 16

By Nicholas G. Miller

The stock of Structure Therapeutics rose after the company reported positive topline data from a phase two study of its aleniglipron oral GLP-1 drug.

The stock rose 8% to $58.07 in premarket trading and has more than doubled over the past 12 months.

The company said the drug showed the highest efficacy among oral GLP-1 drugs and comparable efficacy to injectable GLP-1s.

The drug showed placebo-adjusted mean weight loss of 16.3% at 180 milligrams and 16.0% at 240 milligrams at 44 weeks with no evidence of weight loss plateau.

"The consistent weight loss observed across multiple studies to date reaffirms aleniglipron's potential to be a best-in-class oral GLP-1, with injectable-like efficacy that could become a backbone oral small molecule therapy for obesity," said Chief Executive Raymond Stevens.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

March 16, 2026 08:41 ET (12:41 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2619463573"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619463573\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619463573?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 20:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619463573","market":"hk","top_or_hot":-1,"title":"Structure Stock Rises on Positive Data From Oral GLP-1 Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  The stock of Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company reported positive topline data from a phase two study of its aleniglipron oral GLP-1 drug. \n</p>\n<p>\n  The stock rose 8% to $58.07 in premarket trading and has more than doubled over the past 12 months. \n</p>\n<p>\n  The company said the drug showed the highest efficacy among oral GLP-1 drugs and comparable efficacy to injectable GLP-1s. \n</p>\n<p>\n  The drug showed placebo-adjusted mean weight loss of 16.3% at 180 milligrams and 16.0% at 240 milligrams at 44 weeks with no evidence of weight loss plateau. \n</p>\n<p>\n  \"The consistent weight loss observed across multiple studies to date reaffirms aleniglipron's potential to be a best-in-class oral GLP-1, with injectable-like efficacy that could become a backbone oral small molecule therapy for obesity,\" said Chief Executive Raymond Stevens. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 08:41 ET (12:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Structure Stock Rises on Positive Data From Oral GLP-1 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStructure Stock Rises on Positive Data From Oral GLP-1 Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-16 20:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  The stock of Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company reported positive topline data from a phase two study of its aleniglipron oral GLP-1 drug. \n</p>\n<p>\n  The stock rose 8% to $58.07 in premarket trading and has more than doubled over the past 12 months. \n</p>\n<p>\n  The company said the drug showed the highest efficacy among oral GLP-1 drugs and comparable efficacy to injectable GLP-1s. \n</p>\n<p>\n  The drug showed placebo-adjusted mean weight loss of 16.3% at 180 milligrams and 16.0% at 240 milligrams at 44 weeks with no evidence of weight loss plateau. \n</p>\n<p>\n  \"The consistent weight loss observed across multiple studies to date reaffirms aleniglipron's potential to be a best-in-class oral GLP-1, with injectable-like efficacy that could become a backbone oral small molecule therapy for obesity,\" said Chief Executive Raymond Stevens. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 08:41 ET (12:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLP","symbol_name":"Global Partners Lp","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2619463573","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619463573","pubTimestamp":1773664860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"The stock of Structure Therapeutics rose after the company reported positive topline data from a phase two study of its aleniglipron oral GLP-1 drug.The stock rose 8% to $58.07 in premarket trading and has more than doubled over the past 12 months.The company said the drug showed the highest efficacy among oral GLP-1 drugs and comparable efficacy to injectable GLP-1s.The drug showed placebo-adjusted mean weight loss of 16.3% at 180 milligrams and 16.0% at 240 milligrams at 44 weeks with no evidence of weight loss plateau.\"The consistent weight loss observed across multiple studies to date reaffirms aleniglipron's potential to be a best-in-class oral GLP-1, with injectable-like efficacy that could become a backbone oral small molecule therapy for obesity,\" said Chief Executive Raymond Stevens.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLP":"Global Partners Lp","GPCR":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","BK4144":"石油与天然气的储存和运输","BK4599":"减肥药","BK4007":"制药","BK4590":"PTP"},"translate_title":"结构股因口服GLP-1研究的积极数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GPCR":0.9,"GLP":1.5},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  The stock of Structure Therapeutics rose after the company reported positive topline data from a phase two study of its aleniglipron oral GLP-1 drug. \n\n\n  The stock rose 8% to $58.07 in premarket trading and has more than doubled over the past 12 months. \n\n\n  The company said the drug showed the highest efficacy among oral GLP-1 drugs and comparable efficacy to injectable GLP-1s. \n\n\n  The drug showed placebo-adjusted mean weight loss of 16.3% at 180 milligrams and 16.0% at 240 milligrams at 44 weeks with no evidence of weight loss plateau. \n\n\n  \"The consistent weight loss observed across multiple studies to date reaffirms aleniglipron's potential to be a best-in-class oral GLP-1, with injectable-like efficacy that could become a backbone oral small molecule therapy for obesity,\" said Chief Executive Raymond Stevens. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 08:41 ET (12:41 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}